The Illinois Health department has been reported to have limited the state's AIDS Drug Assistance Program to recent applicants whose incomes are either at 300% of the federal poverty level or below it. Those above the stipulated income percentage will not legible for the program.

Owing to reductions in government spending on programs for low-income earning Americans with HIV, Abbot Laboratories announced the reduction of the cost of their AIDS drug Kaletra in their annual shareholders meeting.

The North Chicago-based Abbott Laboratories stated that the prices most AIDS drug assistance programs will pay for Kaletra will be reduced by 8 percent, to $5,037 each year.

Also, the state and federal records have revealed that there are over 7,700 people waiting for the drug assistance programs. Kaletra is said to be a protease inhibitor, which is a major ingredient in the varieties of medicines HIV patients take to regulate the virus.

However, the Chairman and Chief Executive of Abbot, has expressed that the company had not increased the price of Kaletra since 2007, though other companies have the prices of their AIDS drugs increased to 5-6% yearly.